Prevacid Decline Is Weak Spot In Otherwise Strong Quarter For Abbott
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott posts robust 14% sales growth for the quarter driven by strong Humira performance, but acknowledges that Prevacid sales will be down as much as 10% for full year. The company believes, however, that the upside from Humira outweighs any downside from the performance of the TAP joint venture.
You may also be interested in...
Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA
The company plans to complete the NDA filing for Xinlay in metastatic prostate cancer by year-end, which is ahead of the timetable predicted after a pivotal trial failed to reach statistical significance. A Phase III trial in a second indication is likely to finish in 2005.
Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA
The company plans to complete the NDA filing for Xinlay in metastatic prostate cancer by year-end, which is ahead of the timetable predicted after a pivotal trial failed to reach statistical significance. A Phase III trial in a second indication is likely to finish in 2005.
Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott
Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.